HTA-O

The value derived from health technologies—such as pharmaceuticals, medical devices, diagnostics, and digital health solutions—is highly dependent on their clinical, economic, and societal context. For more insights, refer to standard HTA frameworks and guidelines (e.g., EUnetHTA, NICE, ICER).

This highlights the necessity for a systematic and digital approach to model the HTA context, enabling consistent, transparent, and reproducible assessment of value across different technologies, indications, and healthcare systems.

This ontology is grounded in established standards and frameworks for health technology assessment and healthcare decision-making, namely:

    • EUnetHTA Core Model
    • NICE Evidence Standards Framework
    • ISPOR Value Assessment Frameworks
    • WHO Health Intervention and Technology Assessment Guidelines

Objective

The objective is to standardize, for both humans and machines, the concepts and relationships used to assess the value of health technologies across clinical, economic, patient, ethical, and organizational dimensions. By providing machine-readable and actionable standards, the framework enables transparent and interoperable value assessment, automation of evidence synthesis and economic modeling, streamlined reporting and submissions, and advanced insights such as comparative effectiveness analysis, unmet need identification, and risk and uncertainty evaluation across healthcare systems.

Who would benefit from it?

Any organization involved in the lifecycle of health technologies, including:

  • pharmaceutical and biotechnology companies
  • medical device manufacturers
  • health authorities and HTA agencies
  • payers and insurance organizations
  • healthcare providers and hospital systems